Self-assembled biomimetic nanocomposite integrating defect-enhanced piezoelectricity with NIR-II fluorescence and MR imaging for ultrasound-triggered piezo/chemodynamic therapy of subcutaneous glioma.

Authors

Ikram Hasan, Zia Ullah, Fei Wang, Li Wang, Yibin Yan, Tingting Gong, Muhammad Madni, Dhananjoy Mondal, Hanyang Qu, Jhilik Roy, Yinghe Zhang, Shubham Roy, Bing Guo, Chunqi Chang

Published in

Journal of nanobiotechnology. Jun 26, 2026. Epub Jun 26, 2026.

Abstract

Multifunctional theranostic nanoplatforms enabling precise targeting and controlled deep tissue therapy are vital. Herein, we present a self-assembled, defect-engineered, biomimetic nanoplatform (CDMBBTO), in which piezoelectric material and downconversion nanoparticles (DCNPs) are co-assembled within a polymer matrix, preventing interactions between both components, thereby allowing each to retain its intrinsic properties while collectively enabling dual second near infrared fluorescence (NIR-II FL)/magnetic resonance (MR) imaging and synergistic piezo/chemodynamic therapy (PZDT/CDT). Mn/Bi codoped piezoelectric BaTiO₃ (MBBTO) NPs exhibit a significantly enhanced piezoelectric coefficient (~5 fold higher than pristine BTO) owing to bandgap modulation induced by defect engineering. The incorporated Mn²⁺ not only catalyzes Fenton like reactions for sustained tumor suppression but also provides strong T₂ weighted MR contrast. Self-assembled NIR-II emissive DCNPs enable deep tissue optical imaging, forming an integrated theranostic system. Cloaking of U87 glioma cell membranes imparts homologous tumor targeting capability. In vivo dual modal imaging reveals efficient tumor accumulation, with peak NIR-II FL and MR signal intensities observed 6 h post-injection. Upon ultrasound activation, CDMBBTO elicits potent tumor ablation through synergistic reactive oxygen species generation and immune modulation, characterized by macrophage polarization (M2 → M1) and upregulation of proinflammatory cytokines (TNF-α and IL-6). This work establishes CDMBBTO as a powerful nanoplatform for dual modal imaging-guided, immune potentiated PZDT/CDT toward effective glioblastoma treatment.

PMID:
42363243
Bibliographic data and abstract were imported from PubMed on 27 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.